Related Stories
Photos
Quotations
JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.
Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought →
